New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

Our immune system is great at fighting many types of cancer, but it struggles to see prostate tumors. While new treatments have been game-changers for lung cancer and skin cancer, prostate cancer ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...

A major study of nearly 19,000 men has found that a baldness drug significantly cut the risk of prostate cancer, but its side effects may keep many from using it to prevent what has become the second ...

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...

Add Yahoo as a preferred source to see more of our stories on Google. Hormonal changes in a man's aging body can cause the prostate to grow—resulting in urinary problems since the gland is wrapped ...